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Objectives. This study prospectively evaluated whether early as- 
sessment with adenosine thallium-201 tomography could better 
refine risk stratification on the basis of absolute xtent of myocardial 
ischemia in postinfaretion patients in clinically stable condition. 
Background. Postinfarction patients are at increased risk for 
subsequent cardiac events. However, identifying high risk patients 
among those with residual myocardial ischemia is suboptimal. 
Methods. All 146 patients enrolled underwent assessment of left 
ventricular function and had adenosine tomography performed 
early (mean [-+SD] 5 -+ 3 days) after infarction. Excluded from 
analysis were 51 patients with revascularization after scintigraphy 
and 3 lost to follow-up. Statistical risk models were therefore 
generated from the remaining 92 patients. 
Results. Cardiac events occurred in 30 (33%) of 92 patients over 
15.7 _+ 4.9 months. Univariate predictors of all events were 
quantified perfusion defect size (p < 0.0001), absolute extent of 
left ventricular ischemia (p < 0.000001) and ejection fraction (p < 
0.0001). Risk was best predicted by Cox analysis on the basis of 
1) absolute extent of ischemia and ejection fraction (chi-square 
24.6); 2) percent infarct zone ischemia and ejection fraction 
(chi-square 24.4); or 3) total perfusion defect size and percent 
infarct zone ischemia (chi-square 18.9). The variables that pre- 
dicted all cardiac events were equally powerful at predicting only 
death and nonfatal reinfarction. Death was best predicted by total 
perfusion defect size. 
Conclusions. Risk analysis of individual patients early after 
infarction is feasible on the basis of the quantified extent of 
scintigraphic ischemia and severity of left ventricular dysfunction. 
(JAm Coil Cardio11995;25:1333-40) 
It has long been appreciated that a significant subset of patients in 
clinically stable condition after myocardial infarction have a 
recurrent cardiac event over the ensuing year. Traditionally, this 
high risk group has depressed left ventricular function (1,2), 
residual myocardial ischernia, or both (3-10). The latter is in- 
creasingly relevant because of the widespread use of thrombolytic 
agents that reduce infarct size (11,12) but increase the potential 
for ischemia within the reperfused zone. 
Pharmacologic vasodilators, such as dipyridamole and 
adenosine, have added diagnostic flexibility for assessing pa- 
tients early after infarction when used in conjunction with 
perfusion scintigraphy (6-9,13). Although dipyridarnole planar 
imaging precisely detects low risk patients as those without 
residual ischernia, the positive predictive accuracy of the test is 
low (6-9). However, these studies did not quantify the extent 
of scintigraphic ischemia. The important advance with torno- 
graphic imaging is that the presence and extent of ischernic 
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myocardium are accurately quantified (13-15), which may add 
precision in predicting individual patient risk. 
Based on the hypothesis that cardiac risk is related to the 
extent of both infarcted and jeopardized myocardium, we 
prospectively evaluated whether quantitative adenosine to- 
mography could predict subsequent cardiac events after hos- 
pital discharge in postinfarction patients in otherwise clinically 
stable condition. New statistical models were developed for 
predicting individual patient risk on the basis of broadly 
accepted clinical, functional, angiographic and scintigraphic 
variables. 
Methods  
Patients. The study included 146 consecutive patients (114 
men, 32 women; mean [+SD] age 51 + 11 years, range 31 to 
91) who underwent adenosine tomography early (5 + 3 days) 
after acute myocardial infarction. The protocol was approved 
by our Institutional Review Board, and all patients signed 
written informed consent. This study included 119 patients 
from a previously published series assessing the utility of 
adenosine tomography early after infarction (13). All of the 
patients enrolled were asymptornatic at hospital discharge, but 
43 had experienced transient chest pain or heart failure at 
some time early after infarction. 
Myocardial infarction was diagnosed if patients had pro- 
longed chest pain and met typical electrocardiographic and 
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enzymatic riteria (15). All patients were in clinically stable 
condition at the time of imaging (i.e., no chest pain, cardio- 
genic shock or heart failure), and none were receiving intra- 
venous nitroglycerin or inotropic drugs. Patients with absolute 
contraindications to adenosine were excluded (13). Coronary 
angiography was performed in all but four patients within 1 _+ 
15 days of scintigraphy. The decision to perform angiography 
was not mandated by the investigators but was at the discretion 
of the patient's cardiologist. Left ventricular function was 
assessed by gated radionuclide angiography (n = 28), echocar- 
diography (n = 85) or contrast cineangiography (n = 33). We 
previously reported excellent correlations between these tech- 
niques for assessing ejection fraction at our institution (16-18). 
Coronary revascularization was performed within several 
days (median 3) after scintigraphy in 51 of the 146 patients. 
The data from these patients were not used to generate the 
mathematical risk models. Revascularization was performed in
eight patients with recurrent chest pain and in another nine 
with heart failure. Thirty-four patients in clinically stable 
condition underwent angioplasty (n = 24) or bypass urgery 
(n = 10) at the discretion of their cardiologist. Three patients 
were lost to follow-up. The remaining 92 patients were pro- 
spectively followed up for 15.7 + 4.9 months and constitute the 
study group. 
Baseline characteristics were similar in the 92 study patients 
and in the 51 with vascularization, except hat the latter had 
larger total and ischemic perfusion defects and more frequent 
patency of the infarct-related artery (Table 1). The frequency 
of multivessel coronary artery disease (48% vs. 53%) and mean 
ejection fraction (47%) were comparable in the two groups. 
Protocol for adenosine thallium tomography. Adenosine 
was infused intravenously up to a maximal dose of 140/zg/kg 
body weight per rain, followed by injection of 3 mCi thallium- 
201 (13,19). This standard osing protocol is well tolerated and 
safe (13,19). Thallium-201 tomography was performed as 
previously reported from our laboratory (13). Imaging com- 
menced 5 rain after completing the infusion and was repeated 
4 h later. The tomographic images were quantified using 
standard computer-generated polar maps to define the total 
left ventricular perfusion defect size and extent of scar and 
ischemia (13,15). The percent ischemia within the infarct zone 
was computer quantified by dividing the pixels exhibiting 
thallium redistribution by the total number of abnormal pixels 
within a specific vascular territory on the polar map and 
multiplying by 100. The vascular territories of the three major 
coronary arteries were assigned as previously reported (13). 
Cardiac events. Prospective follow-up after hospital dis- 
charge was accomplished through periodic telephone inter- 
views with patients and their cardiologists. Medical records 
were carefully reviewed and all events confirmed by the 
patient's cardiologist. Cardiac events were prospectively de- 
fined as 1) cardiac death; 2) nonfatal reinfarction; 3) unstable 
angina pectoris (i.e., rest or worsening exertional pain requiring 
hospital admission and associated with transient ST segment 
changes but no increase in cardiac enzyme levels); and 4) signs 
and symptoms of severe congestive heart failure (i.e., pulmona~ 
edema) necessitating hospital admission. Cardiac death was 
further defined as 1) sudden (occurring within 1 h of symptom 
onset and presumably arrhythmic n nature) or 2) reinfarction, 
leading to progressive pump failure and death. 
Statistical analysis. Baseline differences in patients with 
and without subsequent cardiac events were determined using 
unpaired t tests. Data not normally distributed required the 
Wilcoxon rank sum test. Chi-square analysis was used to 
compare discrete data variables. Freedom from all cardiac 
events was plotted by the standard method of Kaplan and 
Meier using STATA statistical software (20,21). Differences in 
"freedom from events" were compared using the log-rank test. 
To generate two groups for univariate comparison, interval- 
scaled covariate cutoffs were selected to allocate roughly equal 
numbers of cardiac events in each group. The Cox propor- 
tional hazards model (STATA) was used to find multivariate 
predictors of cardiac events. A forward stepwise selection 
method was used where subsequent covariates were required 
to add to the current model at p -< 0.05. The proportional 
hazards assumption was tested in BMDP2L, where time and 
time squared by covariate interaction terms were introduced to 
the two covariate models (22,23). Time by covariate interaction 
terms contributed to the model only at p > 0.22, failing to 
disprove the proportionality assumption. 
Predicted probability of remaining free from an event was 
calculated using covariate mean values for the groups of 
interest and the relation exp(Z)S(t) = So(t), where S(t) = 
predicted probability of remaining free from an event; So(t) = 
baseline "freedom from events" function; and Z = E~_ 1 bizi, 
where b i = Cox model covariate coefficients; z i = covariate 
values for the group or individual of interest; and N = number 
of predictive covariates. Comparison of events in patients who 
did and did not undergo revascularization was performed using 
chi-square analysis and the Cox-derived regression models. 
The relative value of scintigraphic and ejection fraction data to 
clinical variables for predicting risk was analyzed by global 
chi-square analysis, which tests whether all model regression 
coefficients are identically zero. Results are presented as mean 
value _+ SD; p < 0.05 was considered significant. 
Resu l ts  
Baseline characteristics of study patients (Table 1). The 
study patients were predominantly middle-aged men, of whom 
36% received thromboiytic therapy during the initial hours of 
infarction. Forty-six percent had anterior infarction, with Q 
waves developing in 76% of patients. Mean left ventricular 
ejection fraction was 47 _+ 15%. 
Cardiac events. Thirty (33%) of the 92 patients had either 
nonfatal reinfarction (  = 12), death (n -- 8), unstable angina 
(n = 7) or congestive heart failure (n = 3). The eight cardiac 
deaths were either sudden (n = 6) or due to reinfarction (  = 
2). Three of 12 patients with reinfaretion and 4 of 7 with 
unstable angina underwent revascularization after these 
events. Mean time from hospital discharge to all events was 
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Table 1. Baseline Clinical and Diagnostic Characteristics 
All Pts Pts With Revasc Pts With No Events Pts With Events 
(n - 92) (n 51) p Value (n = 62) (n = 30) p Value 
Characteristic 
Age (yr) 59 2 11 59 + 12 NS 58 ± 10 62 + 12 0.09 
Male/female 71/21 (77%) 41/10 (80%) NS 51/11 (82%) 20/10 (67%) 0.09 
Killip class I 70/92 (76%) 41/51 (80%) NS 50/62 (81%) 20/30 (67%) NS 
Complications* 26/92 (28%) 17/51 (33%) NS 14/62 (23%) 12/30 (40%) NS 
Thrombolytic Rx 33/92 (36~) 29/51 (57%) 0.02 24/62 (39%) 9/30 (30%) NS 
Prior MI 10/92 (119~) 6/51 (12%) NS 4/62 (6%) 6/30 (20%) 0.05 
Prior CABG 16/92 (17c, i ) 4/51 (8%) NS 7/62 (11%) 9/30 (30%) 0,026 
MI Type 
Anterior 42/92 (46~) 30/51 (59%) NS 28/62 (45%) 14/30 (47%) NS 
Q wave 70/92 (76%) 44/51 (86%) NS 47/62 (76%) 23/30 (77%) NS 
CAD extent (>50% stenosis) 
0 or 1 vessel 46/88 (52%) 24/51 (47%) NS 35/61 (57%) 11/27 (41%) NS 
2 vessels 39/88 (44c:~) 16/'51 (31%) NS 23/61 (38%) 16/27 (59%) NS 
3 vessels 3/88 (492) 11/51 (22%) 0.0001 3/61 (5%) 0/27 (0%) NS 
CAD severity (>50% stenosis) 
LAD 84 ± 18% 84 ± 14% NS 83 + 17% 86 ~ 19% NS 
RCA 92 ± 14% 89 ± 13% NS 90 + 15% 96 ± 7% NS 
Cx 84 = 17~,:~ 80 ± 17% NS 80 ± 18% 90 ± 15% NS 
IZ stenosis 86 + 185i 87 _+ 12% NS 85 z 18% 90 ± 17% NS 
Non-lZ stenosis 81 + 18% 84 ± 16% NS 78 + 18% 87 2 16% NS 
CAD location (>50% stenosis) 
LAD 61/88 (69%) 42/5l (82°4) 0.07 40/61 (66%) 21/27 (78%) NS 
RCA 48/'88 (55%) 28/51 (55%) NS 34/61 (56%) 14/27 (52%) NS 
Cx 38/88 (43%) 19/'51 (37%) NS 21/61 (34%) 17/27 (63%) 0.013 
IRA patency 40/88 (45%) 36/5 l (71%) 0.009 32/61 (52%) 8/27 (30%) 0.047 
Collateral flow to IRA 30/88 (34%) 14/51 (27%) NS 21/61 (34%) 9/27 (33%) NS 
Scintigraphic variable 
Q PDS (total) 28 + I9% 36 _+ 17% 0.006 23 _+ 20% 38 ± 15% < 0.0001 
Q PDS (ischemia) 12 + 11% 17 ± 14% 0.02 9 ± 9% 20 z 12% 0.0001 
Q PDS (sear) 16 = 14% 19 ± 14% NS 14 + 15% 18 _* 11% NS 
Q LAD ischemia 42 ± 26% 50 ± 32% NS 37 ± 24% 50 ± 27% 0.07 
Q RCA ischemia 51 + 34% 58 ___ 28% NS 47 _+ 33% 59 -+ 35% NS 
O Cx ischemia 55 + 36% 63 ± 32% NS 46 ± 36% 67 -+ 34% NS 
Q IZ ischemia 38 ± 27% 45 _+ 28% NS 35 ± 27% 46 ± 25% 0.047 
Q non-IZ ischemia 70 - 33% 66 ~- 26% NS 66 + 34% 73 _+ 33% NS 
Q PDS (->20% LV) 51/92 (55%) 43/5i (84%) (/.0005 26/62 (42%) 25/30 (83%) 0.0005 
LVEF 47 + 15% 47 _+ 12% NS 50 ± 14% 40 ± 14% 0.002 
LVEF (>40%) 64/92 (70q4) 38/51 (74%) NS 50/62 (81,°/6) 14/30 (47%) 0.001 
*Transient chest pain or heart failure during hospital period. Data presented are mean value + SD or number (%) of patients (Pts). CABG = coronary artery 
bypass graft surgery; CAD = coronary artery disease; Cx - circumflex coronary artery; EF = ejection fraction; IRA = infarct-related artery; IZ = infarct zone; LAD = 
left anterior descending coronary, artery; LV = left ventricular; MI -- myocardial infarction; PDS = perfusion defect size; Q = quantified; RCA = right coronary artery; 
Revasc - revascularization. 
7.9 -+ 6.8 months (median 5.4), with 53% occurring within the 
first 6 months. 
Univariate predictors of cardiac events. Patients with 
events tended to be older, and a larger proportion had 
previous infarction, coronary bypass surgery and occlusion of 
the infarct-related artery. The scintigraphic variables best 
defined patient risk, particularly total left ventricular perfusion 
defect size and absolute extent of ischemia (Tables 1 and 2). 
All patients who died had a ->30% perfusion defect. Left 
ventricular ejection fraction was also highly predictive of 
cardiac events (p = 0.002) but in an inverse manner. 
Kaplan-Meier curves depicting event-free survival were 
generated for specific dichotomized variables (Fig. 1). The 
curves displayed for perfusion defect size and ejection fraction 
are similar but inversely related (Fig. 1A). Patients with a 
perfusion defect <20% or ejection fraction >40% had a 
comparably low 1-year event rate. The absolute extent of 
scintigraphic ischelnia best defined risk (Fig. 1B). More than 
50% of patients with a >10% ischemic defect had an event by 
1 year versus 10% of patients with a defect -<10%. Similar 
results were observed for infarct-flee survival (Fig. 1C) and for 
patients stratified according to reperfusion therapy during 
acute infarction (Fig. 1D). The positive and negative predictive 
values for detecting all events with ejection fraction dichoto- 
mized at 40% were 45% and 89%, with similar values for 
scintigraphic ischemia (40% and 92%) when dichotomized at 
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Table 2. Adenosine Single-Photon Emission Computed Tomographic Perfusion Defect Size: 
Cardiac Events 
Cardiac Event 
No Cardiac 
Event RM1/UA Death/'RMI CHF/Death Total 
PDS (n = 62) (n 19) (n = 20) (n = 11) (n = 30) 
Total (%) 23 : 20 32 : 14 38 ~ 16' 48 _+ 10' 38 _+ 15' 
lschemia (9; 9 ± 9 18 : ll* 21 ± 12" 23 ± 13" 20 = 12' 
Scar (%,) 14 ± 15 14 ± 10 17 ± 12 25 ± II 18 + 11 
*p < 0.001 versus no events. Data presented are mean value _+ SD. CHF = congestive heart failure; PDS = perfusion 
defect size; RMI = recurrent myocardial infarction: UA = unstable angina. 
10%, respectively. The angiographic extent of coronary, disease 
did not identify a high risk group (Fig. 1B). 
Multivariate predictors of cardiac events (Table 3, Fig. 2). 
When the variables in Table 1 were assessed ina stepwise Cox 
Figure 1. Kaplan-Meier curves depicting freedom from cardiac events 
on the basis of (A) left ventricular (LV) perfusion defect size (PDS) 
and ejection fraction (EF); and (B) quantified extent of left ventricular 
ischemia (QISCH) and coronag, artery, disease. Quantified extent of 
ischemia best separates low and high risk patients. Similar results are 
observed for patients who died or had nonfatal reinfarction (C). 
Quantified extent of ischemia predicted risk irrespective of initial 
therapy during acute infarction (solid lines - early reperfusion 
therapy: dashed lines = no early reperfusion therapy) (D). MI 
myocardial infarction: MVD multivessel disease: SVD = single 
vessel disease. 
regression analysis, three models were found to best predict 
individual patient risk (Table 3) and are illustrated in Figure 2. 
where derived probabilities of having a clinical event by 1 year 
were plotted against pairs of predictive covariates. Super-. 
imposed on these probabilities are the actual outcomes for alt 
92 patients. Figure 2 reflects the agreement between the model 
and actual results. The slope of the probability lines represent 
the relative importance of the X- and Y-axis covariates in 
predicting risk. The specific lines computed are for illustrative 
purposes only and provide a model-based estimate of pre- 
dicted risk for a postinfarction patient. 
The most powerful model (model 1) was based on the 
absolute xtent of scintigraphic ischemia nd ejection fraction. 
For every 10% increment in these variables, risk increased by 
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Table 3. Models for Predicting Long-Term Cardiac Events* 
Relative 95% Confidence 
Events Variable Risk¢ Interval p Value 
Total 
Model 1 QISCH 1.82 1.33-2.48 < 0.001 
Chi-square (2 df) - 24.6 LV EF 0.76 0,59-0.99 0.045 
Model 2 IZI 1.33 1,14-1.56 0.001 
Chi-square (2 df) - 24.4 LV EF 0.55 0.41-0.73 < 0.001 
Model 3 PDS 1.38 1,16-1.64 0.001 
Chi-square (2 df) 18.9 IZI 1.26 1,08-1.46 0.004 
Death/RMI 
Model 1 QISCH 1.80 1.21-2.70 0.004 
Chi-square (2 df) 22.2 LV EF 11.64 0,46-0.90 0.01 
Model 2 IZ1 1.41 1.1-1.75 0.003 
Chi-square (2 dr) = 24.0 LV EF 0.44 0.30-0.65 < 0.00l 
*See text for explanation f models 1to 3. ?Based on 10% absolute increments in each variable, df- degrees of
freedom; IZI - % infarct zone ischemia; QISCH - quantified absolute %left ventricular ischemia; other abbreviations 
as in Table 1. 
82% or decreased by 32%, respectively. Only female gender 
added to the model (p = 0.03). Although an excellent outcome 
is predicted for patients with an ejection fraction >40% and no 
residual ischemia, risk markedly increases according to the 
extent of myocardial ischemia (Fig. 2A and 3). 
In model 2, percent infarct zone ischemia and global 
ejection fraction defined risk (Table 3). Advancing age and 
lack of collateral vessels to the infarct-related artery only 
tended to improve this model. Model 3 was based solely on 
scintigraphic variables (Table 3, Fig. 2B). The derived mathe- 
matical models accurately portrayed actual patient results (Fig. 
2) and predicted risk equally well in patients who did and did 
not receive perfusion therapy during acute infarction (Fig. 
1D). 
Infarct-free survival was best predicted from the variables 
used in models 1 and 2 (Table 3, Fig. 2C). Death was best 
predicted by the total perfusion defect size, irrespective of all 
other variables (relative risk 1.62 for 10% increments indefect 
size, 95% confidence interval 1.23 to 2.12, p = 0.001). 
Incremental value of scintigraphie and ejection fraction 
variables. Chi-square values for predicting overall risk, de- 
rived from readily available clinical characteristics, were com- 
pared with left ventricular ejection fraction and scintigraphic 
variables (Fig. 4). The base clinical model included patient age, 
gender, previous infarction and previous bypass urgery, vari- 
ables that had univariate significance (Table 1). Coronary 
angiographic variables did not improve the clinical model for 
predicting patient risk. Adding ejection fraction or perfusion 
defect size to the clinical model significantly improved the 
chi-square value, particularly when scintigraphic schemia was 
added. Similar results were observed for infarct free survival 
(Fig. 4). These findings are consistent with the forward- 
selected Cox models, which showed the overwhelming power 
of ejection fraction and scintigraphic variables over clinical or 
angiographic variables for predicting risk. 
Cardiac events in patients undergoing revascularization 
early after scintigraphy. In the 36 patients who had coronary. 
angioplasty after scintigraphy, the infarct-related artery was 
successfully dilated (<50% residual stenosis) in 22 with single- 
vessel and 12 of 14 patients with multivessel disease. In the 
latter group, 17 (68%) of 25 arteries with significant (>50%) 
stenosis and scintigraphic schemia within their vascular bed 
were successfully dilated. The 15 patients who underwent 
bypass urgery had predominantly double-vessel (n = 7) or 
triple-vessel (n : 6) disease, and complete revascularization 
was performed as technically feasible. 
Eight (16%) of the 51 patients with revascularization re- 
turned with a cardiac event over 16.0 _+ 4.7 months of 
follow-up--all readmissions for unstable angina. The event 
rate was significantly less in patients with revascularization 
(l 6%) than in those medically managed (33%, p = 0.028), with 
improved infarct-free survival (100% vs. 78%, p = 0.0005). On 
the basis of statistical models generated from the 92 patients 
without rcvascularization, a 35% 1-year event rate was ex- 
pected for those with revascularization. I stead, only a 16% 
event rate was observed. In the patients without revasculariza- 
tion, the predicted and observed 1-year event rates were 
comparable at 29% and 33%, respectively. 
Discuss ion  
Strategies for assessing risk in patients after myocardial 
infarction have gained considerable attention over the past 
decade. To our knowledge, this study is the first to explore the 
potential of combining the absolute extent of myocardial 
ischemia, as assessed by quantitative adenosine tomography, 
with left ventricular ejection fraction for defining long-term 
risk. Our data support hat the absolute xtent of scintigraphic 
ischemia is a strong predictor of overall cardiac risk, especially 
when combined with ejection fraction. While this study con- 
firms the finding that absence of ischemia portends an excel- 
lent prognosis, it also provides new insight for defining risk in 
patients with residual ischemia on the basis of absolute xtent 
present. 
Optimizing risk stratification. In this era of increasing 
emphasis on cost-containment, postinfarction patients in stable 
condition should be risk stratified using noninvasive testing. 
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Figure 2. Cox regression models displaying 1-year isk for a cardiac 
event according to left ventricular (LV) ejection fraction and total left 
ventricular ischemia (A) or scintigraphic variables (B). Regression 
model for predicting infarct-free survival is displayed in C. Diagonal 
lines = representative isobars of percent risk. Patient risk for any 
cardiac event (A), or specifically death and nonfatal reinfarction (C), 
increases as total left ventricular ischcmia increases and left ventricular 
ejection fraction decreases or as total perfusion defect size and percent 
infarct zone ischemia increase (B). For any given left ventricular 
ejection fraction (A and C) or perfusion defect size (B), risk varies 
widely depending on the amount of ischemia. Left ventricular ejection 
fraction and scintigraphic results for each of the 92 patients who did 
(solid circles) or did not (open circles) have a subsequent cardiac event 
over the entire follow-up period are plotted against heir calculated 
risk at 1 year (A, B). Patients are plotted in C according to death 
(triangles), nonfatal reinfaretion (solid circles) or neither of these 
events (open circles). 
This allows targeting more expensive and invasive procedures 
to patients most likely to incur a cardiac event. The Throm- 
bolysis in Myocardial Infarction (TIMI) lI trial (24) exempli- 
fies this approach because patients without provokable isch- 
emia who were treated conservatively had an outcome 
comparable to those randomized to a more expensive invasive 
strategy. Our study extends the implications of TIMI II by 
Figure 3. Polar map of a patient with Q wave anterior infarction whc 
had angiographic collateral filling of an occluded left anterior descend- 
ing coronary artery (LAD) and 78% stenosis of the right corona O
artery (RCA). Total perfusion defect size is 54%, with 47% ischemia 
(green) and 7% scar (black) involving the left anterior descending and 
right coronary vascular territories. The patient's calculated risk for an 
event was high at 89%, 67% and 85%, on the basis of models 1 to 3 
despite a well preserved left ventricular ejection fraction of 45%. Thi~ 
patient died within the first month of follow-up. LCx = left circumflex 
coronary artery. 
defining risk in individual patients on the basis of quantified 
extent of ischemia. The tests used to define risk must also be 
widely available, easy to perform and safe. The noninvasive 
techniques tudied in the present investigation meet these 
criteria and are applicable to virtually all postinfarction pa- 
tients without complications, including those unable to exer- 
cise (13,19,25). Whether less costly exercise electrocardiog- 
raphy would have predicted risk similar to scintigraphy is 
unknown because this study used pharmacologic stress only. 
Role of coronary angiography. Coronary angiography is an 
acceptable approach in postinfarction high risk patients in 
unstable condition who are being considered for urgent revas- 
cularization. However, in patients in stable condition, routine 
angiography adds little prognostic information to that obtained 
by noninvasive testing (3,7,9). Cardiac risk is most influenced 
by infarct size and extent of residual ischemia. Because the 
vascular bed of a given coronary artery varies enormously 
among subjects (26,27), the impact of coronary occlusion on 
infarct size and global function is not readily definable. Fur- 
thermore, the patency status of the infarct-related artery does 
not predict myocardial viability (13,28) or improvement in 
regional function after angioplasty (29). Thus, angiography 
cannot assess infarct size or extent of potential injury should 
ischemia recur, thereby limiting its utility in risk stratification. 
Quantifying scintigraphic isehemia. In the present trial, 
thallium-201 tomography was combined with adenosine to 
quantify the extent of jeopardized myocardium. Adenosine is a 
very short-acting (30), primary coronary artery vasodilator that 
can best delineate an abnormal vascular bed by maximizing 
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Figure 4. Incremental prognostic powcr of 40 
scintigraphic variables and left ventricular ejec- 
tion fraction compared with that of a baseline 
clinical model (B) for predicting all events 
(cross-hatched and open bars) or death and 
reinfarction (cross-hatched bar). Consistent 30 
with the Cox hazard models (Table 3), left 
ventricular ejection fraction and perfusion de- 
fect size, but particularly the extent of scinti- "~ 
graphic ischemia (I), independently predict risk -~ 20 
significantly better than the baseline clinical -- 
model (B). Furthermore, xtent of ischemia 
improved the predictive power of the combined 
baseline clinical model and perfusion defect 
size (B+PDS) or baseline model and left yen- 10 
tricular ejection fraction (B+LVEF) for all 
events and for death and reinfarction. Left 
ventricular ejection fraction added to the com- 
bined baseline model and PDS (B+PDS) or the 
baseline model and extent of ischemia (B+I) 
for predicting death and reinfarction. CAD = 
extent coronary artery disease; EF = ejection 
fraction; IRA = infarct artery patency; X 2 = 
chi-square analysis. 
*p=.01 vs B 
tp<.02 vs (B+PDS) 
#p<.004 vs (B+PDS) 
:J:p<.005 vs (B+EF) 
¶p<.02 vs (B÷I) 
20.4* 20.3 
12.2 12.2 
10.3 10.1" 
o 
B B+IRA B+CAD B+PDS B÷EF B+PDS+EF B+I B+PDSH B+EF+I 
heterogeneity in coronary blood flow (31). Single-photon 
tomography can accurately quantify the extent of myocardial 
hypoperfusion as well as the extent of global and infarct zone 
redistribution (ischemia) (13,15). 
The present study demonstrates that adenosine tomogra- 
phy can effectively evaluate cardiac risk in patients in stable 
condition very early after infarction. These findings extend our 
previous results showing that adenosine tomography detects 
high risk patients for in-hospital cardiac events on the basis of 
perfusion defect size and extent reversibility (13). Our present 
results are particularly striking because many presumably high 
risk patients with large ischemic defects underwent revascular- 
ization after the scintigraphic results were known. The predic- 
tive accuracy of scintigraphy might have been even greater had 
these patients not undergone r vascularization a d had been 
entered into the risk analysis. Our study is relevant to present- 
day practice in that many patients received thrombolytic 
therapy (36%) or had angioplasty (16%) during the early hours 
of infarction. Furthermore, the baseline characteristics of our 
study patients are very similar to those reported in the TIMI II 
(24) and Global Utilization of Streptokinase and t-PA for 
Occluded Arteries (GUSTO) (32) trials, which cumulatively 
enrolled >44,000 patients. Although the results of no single 
clinical trial are universally applicable, the patients that we 
enrolled are representative of those currently hospitalized with 
acute infarction. 
To our knowledge our study is the first to stratify long-term 
risk in individual patients on the basis of the presence and 
absolute xtent of scintigraphic schemia. The statistical mod- 
els profile an individual patient's risk over a wide spectrum of 
left ventricular ischemia. For example, the 1-year isk for death 
or reinfarction i patients with a 40% ejection fraction varies 
more than eightfold, depending on the global extent of isch- 
emia (model 1, 9% to >75%) or that present in the infarct 
zone (model 2, 5% to >60%). In patients at low predicted risk 
(i.e., ejection fraction >40% and scintigraphic ischemia 
-<10%), the 1-year infarct-free survival was 94% and that for 
any cardiac event 88%. Importantly, there were no cardiac 
deaths. In this group, which represented 48% of our study 
patients, a conservative strategy without invasive testing would 
seem appropriate. In the remaining patients with significant 
ischemia, the threshold for defining who is at medium or high 
risk will differ among clinicians, but our models clarify that risk 
and should aid in selecting patients for angiography and 
possible revascularization. 
Although not evaluated ina prospective randomized fashion, 
patients with revascularization had a very low cardiac event rate 
(16%) despite an initially similar predicted risk (35%) as those 
without revascularization (29%). Patients with the highest scinti- 
graphic risk may benefit most from very aggressive treatment of
ischemia, whether by an intense medical regimen or coronary 
revascularization. This must first be determined in prospective 
randomized trials. Conversely, the early identification oflow risk 
patients i also relevant because an aggressive invasive strategy in
such patients is of no proved benefit compared with that from 
pharmacologic therapy (24,33). 
Role of perfusion scintigraphy after thrombolysis. The 
statistical models generated for predicting risk appeared 
equally valid for patients who did and did not receive repcr- 
fusion therapies. Indeed, there are few studies to suggest that 
scintigraphy should be any less predictive of cardiac events in 
patients receiving thrombolytic agents. The positive predictive 
value of exercise-induced scintigraphic schemia was recently 
reported to be similar in patients who did (36%) or did not 
(33%) receive reperfusion therapy during acute infarction 
(34). Furthermore, thallium redistribution identified 80% (4 of 
5) of intervened patients who later died or had recurrent 
infarction. Within the limitations of this study (i.e., submaximal 
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exercise, planar imaging, no ischemia quantification), scintig- 
raphy predicted "hard" cardiac events equally well in patients 
with and without intervention. Conversely, patients who re- 
ceive thrombolytic therapy and lack ischemia by noninvasive 
testing have an excellent prognosis with a reported 1-year 
infarct-free survival of 98% (33). These results are consistent 
with reports from the prethrombolytic era emphasizing the 
prognostic importance of scintigraphic ischemia (3-10). 
Clinical implications. The present investigation provides 
new insight into the prognostic importance of quantifying myo- 
cardial ischemia in patients early after infarction. Because resid- 
ual infarct zone ischemia is common even in patients with 
coronary angioplasty as the primary therapy for acute infarction 
(35), quantifying the extent of ischemia might also define long- 
term risk and guide management in such patients. Further 
investigation is warranted to prospectively validate our risk mod- 
els in postinfarction patients and to determine whether educing 
the extent of scintigraphic schemia in high risk patients confers 
benefit and how this might be best accomplished. 
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